Related Experiment Video
Updated: Jun 8, 2025

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
Published on: January 31, 2025
Macrophage LRRK2 hyperactivity impairs autophagy and induces Paneth cell dysfunction
Shengxiang Sun1, Miki Hodel1, Xiang Wang2
1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Abstract:
LRRK2 polymorphisms (G2019S/N2081D) that increase susceptibility to Parkinson's disease and Crohn's disease (CD) lead to LRRK2 kinase hyperactivity and suppress autophagy. This connection suggests that LRRK2 kinase inhibition, a therapeutic strategy being explored for Parkinson's disease, may also benefit patients with CD. Paneth cell homeostasis is tightly regulated by autophagy, and their dysfunction is a precursor to gut inflammation in CD. Here, we found that patients with CD and mice carrying hyperactive LRRK2 polymorphisms developed Paneth cell dysfunction. We also found that LRRK2 kinase can be activated in the context of interactions between genes (genetic autophagy deficiency) and the environment (cigarette smoking). Unexpectedly, lamina propria immune cells were the main intestinal cell types that express LRRK2, instead of Paneth cells as previously suggested. We showed that LRRK2-mediated pro-inflammatory cytokine release from phagocytes impaired Paneth cell function, which was rescued by LRRK2 kinase inhibition through activation of autophagy. Together, these data suggest that LRRK2 kinase inhibitors maintain Paneth cell homeostasis by restoring autophagy and may represent a therapeutic strategy for CD.
Insights
Genetic variants in LRRK2 (Leucine-rich repeat kinase 2) influence Parkinson's and Crohn's disease risk. LRRK2 kinase inhibitors may treat Crohn's disease by restoring Paneth cell function and autophagy.
Area of Science:
- Gastroenterology
- Immunology
- Genetics
Background:
- LRRK2 (Leucine-rich repeat kinase 2) polymorphisms are linked to increased risk of Parkinson's disease and Crohn's disease (CD).
- Hyperactive LRRK2 kinase activity suppresses autophagy, a critical process for maintaining Paneth cell homeostasis.
- Paneth cell dysfunction is implicated in the gut inflammation characteristic of CD.
Purpose of the Study:
- To investigate the role of LRRK2 in Paneth cell dysfunction in CD.
- To explore LRRK2 kinase inhibition as a potential therapeutic strategy for CD.
Main Methods:
- Analysis of LRRK2 polymorphisms in CD patients and mouse models.
- Assessment of Paneth cell function and autophagy.
- Investigation of LRRK2 expression in intestinal cells.
- Evaluation of LRRK2 kinase inhibition effects on Paneth cell function and autophagy.
Main Results:
- CD patients and mice with hyperactive LRRK2 polymorphisms exhibited Paneth cell dysfunction.
- LRRK2 kinase was found to be expressed in lamina propria immune cells, not Paneth cells.
- LRRK2-mediated pro-inflammatory cytokine release impaired Paneth cell function.
- LRRK2 kinase inhibition restored autophagy and rescued Paneth cell function.
Conclusions:
- LRRK2 kinase hyperactivity contributes to Paneth cell dysfunction in CD.
- LRRK2 kinase inhibitors may represent a novel therapeutic approach for CD by restoring autophagy and Paneth cell homeostasis.
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Lysosomal Hydrolases
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...

